Go Deep
Zydus Lifesciences Limited
Zydus Lifesciences Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,926 | 25.1 | 4.14 | 0.42 | 1,124.70 |
Zydus Lifesciences Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 78,020,000,000.0 | 74,344,000,000.0 | 67,804,000,000.0 | 64,670,000,000.0 |
| Net Profit | 9,398,000,000.0 | 12,725,000,000.0 | 10,421,000,000.0 | 14,668,000,000.0 |
| EPS | 9.3 | 12.7 | 10.4 | 14.6 |
Zydus Lifesciences Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 267,197,000,000.0 | 225,738,000,000.0 | 190,215,000,000.0 | 168,778,000,000.0 | — |
| Net Profit | 50,400,000,000.0 | 45,255,000,000.0 | 38,595,000,000.0 | 19,603,000,000.0 | — |
| EPS | 50.1 | 45.0 | 38.1 | 19.3 | — |
Zydus Lifesciences Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 524,066,000,000.0 | 372,017,000,000.0 | 292,808,000,000.0 | 257,564,000,000.0 | — |
| Total Liabilities | 228,244,000,000.0 | 108,433,000,000.0 | 71,792,000,000.0 | 60,681,000,000.0 | — |
| Total Equity | 271,114,000,000.0 | 239,531,000,000.0 | 198,295,000,000.0 | 175,158,000,000.0 | — |
Owes vs Owns
Zydus Lifesciences Limited owed ₹0.44 for every ₹1 it owned in Mar 2026, up from ₹0.24 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.44× | 0.29× | 0.25× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Zydus Lifesciences Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 9.5%Receivables 10.3%Inventory 10.7%Fixed assets (tangible) 20.5%Intangible assets 33.2%Long-term investments 2.2%Other assets 13.5%
How it's funded — Mar 2026
Short-term debt 16.4%Long-term debt 6.1%Payables 5.4%Other liabilities 15.7%Shareholders' equity 56.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 4,971.1 | 5,641.6 | 1,379.7 | 1,206.6 |
| Receivables | 5,415.7 | 4,084.8 | 5,220.2 | 4,416.8 |
| Inventory | 5,628.1 | 3,944.0 | 3,441.9 | 3,413.3 |
| Fixed assets (tangible) | 10,729.7 | 7,559.7 | 7,049.2 | 6,973.1 |
| Intangible assets | 17,407.9 | 8,465.7 | 7,877.0 | 5,894.9 |
| Long-term investments | 1,166.6 | 1,143.1 | 529.4 | 457.6 |
| Other assets | 7,087.5 | 6,362.8 | 3,783.4 | 3,394.1 |
| Liabilities & equity | ||||
| Short-term debt | 8,581.5 | 3,169.5 | 768.6 | 1,163.2 |
| Long-term debt | 3,188.0 | 0.0 | 0.0 | 0.0 |
| Payables | 2,845.1 | 2,280.7 | 2,126.7 | 2,125.0 |
| Other liabilities | 8,209.8 | 5,393.1 | 4,283.9 | 2,779.9 |
| Shareholders' equity | 29,582.2 | 26,358.4 | 22,101.6 | 19,688.3 |
| Net tangible assets | 9,703.5 | 15,487.4 | 11,952.5 | 11,620.9 |
Zydus Lifesciences Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 21,166,000,000.0 | 67,811,000,000.0 | 31,963,000,000.0 | 26,888,000,000.0 | — |
| Investing Activities | -82,961,000,000.0 | -83,578,000,000.0 | -14,752,000,000.0 | 15,350,000,000.0 | — |
| Financing Activities | 58,069,000,000.0 | 19,953,000,000.0 | -17,788,000,000.0 | -44,004,000,000.0 | — |